Evidence map›Paper›PMID 34703030›Full record

ArticleOncogene2022

Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.

Hendrik J Kuiken, Sabin Dhakal, Laura M Selfors, Chandler M Friend, Tian Zhang, Maurizio Callari, Ron C J Schackmann, G Kenneth Gray, Jett Crowdis, Hyo-Eun C Bhang and 5 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Hendrik J Kuiken *Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Sabin Dhakal *Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Laura M SelforsDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Chandler M FriendDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Tian ZhangDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Maurizio CallariCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Ron C J SchackmannDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
G Kenneth GrayDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Jett CrowdisDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Hyo-Eun C BhangDepartment of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA.
Timour BaslanCancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
Frank StegmeierDepartment of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Carlos CaldasCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0003-3547-1489
Joan S BruggeDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. Joan_Brugge@hms.harvard.edu.ORCID http://orcid.org/0000-0002-2547-4814
Harvard University · USNovartis (Switzerland) · CHUniversity of Cambridge · GBBroad Institute · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Use of Organotypic and Mammary Gland Models to Investigate the Outcomes of ClonalP01CA080111 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI DILLON, DEBORAH · 1999 to 2018
$36.0M
Cancer Research UK 16942Cancer Research UK 29567NCI NIH HHS P01 CA080111NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes an in-depth analysis of molecular and functional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line, including copy number analysis, whole-exome and RNA sequencing, proteome analysis, and barcode analysis of clonal dynamics, as well as functional assays. The SCPs were found to have multiple unique genetic alterations and displayed significant variation in anchorage independent growth and tumor forming ability. Analyses of clonal dynamics in SCP mixtures using DNA barcode technology revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts, demonstrating that in vitro propagation of cancer cell lines using different culture conditions can contribute to the establishment of unique strains. These analyses also revealed strong enrichment of a single SCP during the development of xenograft tumors in immune-compromised mice. This SCP displayed attenuated interferon signaling in vivo and reduced sensitivity to the antiproliferative effects of type I interferons. Reduction in interferon signaling was found to provide a selective advantage within the xenograft microenvironment specifically. In concordance with the previously described role of interferon signaling as tumor suppressor, these findings suggest that similar selective pressures may be operative in human cancer and patient-derived xenograft models.

Indexed as

Genetic HeterogeneityAnimalsHumansMiceMutationTriple Negative Breast NeoplasmsTumor Microenvironment

Identifiers

PMID34703030
PMCPMC8727509
OpenAlexW3210982405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.